Each day Hit: January 6, 2022


It’s time on your Each day Hit of hashish monetary information for January 6, 2022.

On The Website


MedMen (OTCQX: MMNFF) continues to be refusing to shut its agreed-upon take care of Ascend Wellness Holdings, Inc. (CSE: AAWH.U) (OTCQX: AAWH) for the properties in New York. The funding, which was agreed upon in March 2021, noticed MedMen signing an settlement with Ascend Wellness Holdings, the place Ascend would make an funding of roughly $73 million in MedMen NY Inc. or MMNY. Following the funding, Ascend would maintain a controlling curiosity in MMNY of roughly 86.7% and may have an possibility to purchase MedMen’s remaining curiosity in MMNY sooner or later. The deal was dependent upon New York State’s approval, which the Workplace of Hashish Administration of the Hashish Management Board of the State of New York gave on December 16, 2021. On January 2, 2022, Ascend mentioned that MedMen tried to terminate the Funding Settlement saying they hadn’t obtained approval from the relevant state regulators to fulfill the closing circumstances. On January 3, 2022, AWH instructed MedMen that its termination try was invalid.  On January 6, AWH reiterated this of their discover to MedMen relating to regulatory compliance.

Vacation Gross sales

Hashish information suppliers have weighed in on the 2021 vacation gross sales for dispensaries with some shocking outcomes. The information included the Thanksgiving vacation after which tracked gross sales by means of to the tip of Christmas. Most agreed that gross sales elevated in 2021 regardless of the resurgence of the brand new Covid concern with the variant Omicron. Customers upped their hashish procuring all through the month of December inflicting Christmas week comparisons to be much less robust than prior to now. Nonetheless, gross sales remained elevated main as much as Christmas in each the Canadian and U.S. markets.

In Different Information


READ ALSO  How To Elevate Your Hashish Expertise To A Complete New Degree

Halo Collective Inc. (OTCQB: HCANF) introduced that it has entered right into a mortgage settlement with World Tech Alternatives 6 for as much as $14,000,000 to Halo in two tranches of $7,000,000 every, topic to sure phrases and circumstances. Quantities superior below the Mortgage Settlement are anticipated for use to assist Halo’s enlargement into nutraceutical merchandise (together with Hushrooms), the completion of Halo’s Budega™ retail shops in North Hollywood, Hollywood, and Westwood, California, and for common company functions. The Mortgage Quantity is unsecured and can bear curiosity at 8.0% every year, and every tranche will probably be repayable in six equal month-to-month installments (of blended principal and curiosity) of $1,194,039.62 per installment. 

Columbia Care

Columbia Care Inc. (CSE:CCHW) (OTCQX:CCHWF) introduced that it’s commencing a solicitation of consents from holders of its 13.00% senior secured notes due Could 14, 2023; 5.00% senior secured convertible notes due December 19, 2023; and 6.00% senior secured convertible notes due June 29, 2025, to think about sure amendments to the belief indenture dated Could 14, 2020, as supplemented, governing the Notes. The important thing modification will considerably enhance the corporate’s borrowing capability to assist development initiatives.


Revive Therapeutics Ltd. (OTCQB: RVVTF) needs to make clear sure disclosures in its press launch titled “Revive Therapeutics Offers Replace on Section 3 Scientific Trial for Bucillamine in COVID-19,” issued on December 29, 2021, that supplied an replace on the Firm’s U.S. Meals & Drug Administration (“FDA”) Section 3 scientific trial  (NCT04504734) to judge the protection and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in sufferers with gentle to reasonable COVID-19. As of December 29, 2021, there have been roughly 700 topics that participated within the enrollment interval of the Examine. The Firm expects affected person enrollment in Turkey to happen by mid-February and completion of the Examine’s enrollment in Q1-2022. The corporate isn’t making any specific or implied claims that its product has the flexibility to eradicate or treatment COVID-19 (SARS-2 Coronavirus) presently.

Publish Views:



The statements made regarding these merchandise haven’t been evaluated by the Meals and Drug Administration. The efficacy of these merchandise has not been confirmed by FDA-approved evaluation. These merchandises are often not meant to diagnose, take care of, treatment, or forestall any sickness. All information discovered proper right here won’t be meant as another choice to or completely different from information from well-being care practitioners. Please search the recommendation of your well-being care expert about potential interactions or completely different attainable points sooner than using any product. The Federal Meals, Drug and Magnificence Act requires this discovery.

READ ALSO  AFC Falls Quick on Income as Tenants Skip Hire